DISCOUNT ZERTIFIKAT - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 20:40:19 03/07/2024 BST | ||
| 405.8 EUR | -0.47% |
|
| Current month | -0.78% | ||
| 1 month | +1.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 405.8 | -0.47% |
| 02/07/24 | 407.7 | -0.18% |
| 01/07/24 | 408.5 | -0.13% |
| 28/06/24 | 409 | 0.00% |
| 27/06/24 | 409 | -0.26% |
Delayed Quote Deutsche Boerse AG
Last update July 03, 2024 at 08:40 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PN2MXU |
| ISIN | DE000PN2MXU6 |
| Date issued | 27/04/2023 |
| Maturity | 20/12/2024 (170 Days) |
| Parity | 1 : 1 |
| Emission price | 301.7 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 410.1 € |
|---|---|
| Lowest since issue | 306.6 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1
USD
Average target price
870.3
USD
Spread / Average Target
-3.10%
- Stock Market
- Certificates
- Certificat
